Gerresheimer Charts Solo Course After Spurning Premium Takeover Bid

The Düsseldorf-based pharmaceutical packaging specialist Gerresheimer has chosen a difficult path of independent recovery, turning down a lucrative takeover offer in favor of confronting a deep-seated accounting scandal. The company rejected an informal bid of 41 euros per share from US packaging giant Silgan in March, a price that was more than double its stock price at the time, according to sources familiar with the matter. Talks between the two firms have since ceased.

With the takeover route closed, management is focusing on a dual strategy: selling a major US subsidiary and untangling a complex web of accounting irregularities. The sale process for the US unit Centor Inc., which makes packaging systems for prescription drugs, is already underway with a double-digit number of interested parties. Investment bank Morgan Stanley is advising on the transaction. Gerresheimer expects the deal to close this year; the division was carried on the books at 292 million euros at the end of 2024. Proceeds are intended to stabilize the company's capital and financing structure.

The core challenge remains a significant accounting crisis. An independent law firm confirmed systematic violations of IFRS rules related to so-called bill-and-hold agreements, where Gerresheimer invoiced customers for goods but delayed shipment, prematurely booking 35 million euros in revenue and 24 million euros in adjusted EBITDA. The German financial regulator, BaFin, has identified concrete evidence of breaches in accounting standards, focusing on three key areas: incorrectly reported lease liabilities, erroneous useful life assumptions for capitalized development costs, and unimpaired assets in the Advanced Technologies segment with a book value of nearly 197 million euros.

This scandal has triggered wider repercussions. The auditor oversight body APAS has initiated professional misconduct proceedings against KPMG, which issued an unqualified audit opinion on the 2024 accounts despite these errors, having only replaced previous auditor Deloitte in 2024. The German shareholder association DSW is examining damage claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner, with a focus on valuation questions surrounding business assets worth approximately 676 million euros.

To navigate this period, Gerresheimer has secured crucial breathing room from its creditors. Holders of 96% of the total volume of 870 million euros in Schuldschein loans agreed to extend a deadline until the end of September 2026. Banking partners have also followed suit, suspending key credit conditions related to leverage ratios through the end of the third quarter.

Operationally, the company states that daily business is meeting expectations with a solid order book. For the current fiscal year, it forecasts revenues between 2.3 and 2.4 billion euros and an adjusted EBITDA margin of 18 to 19 percent. However, the absence of audited financials continues to cast a long shadow. Gerresheimer aims to publish its audited 2025 annual and group financial statements in June, with the half-year report scheduled for July 14, 2026.

The stock market reaction has been volatile. Following the news that Silgan's offer was rejected, the share price briefly fell five percent but recovered quickly. The stock currently trades around 22.32 euros, representing a loss of roughly 57 percent over the past twelve months and standing far below its 52-week high of 64.40 euros. Despite this, some institutional investors like the CastleKnight Master Fund and Deka Investment have recently reported new stakes, betting on a potential stabilization.

Every new development from the regulatory front remains a potential catalyst for the stock—in either direction. The company's immediate future hinges on delivering a clean audit in June and successfully concluding the Centor sale, pivotal steps to restore credibility and attract sustained institutional capital.

Ad

Gerresheimer Stock: New Analysis - 22 April

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gerresheimer analysis...